Deutsche Bank Aktiengesellschaft Raises Corteva (NYSE:CTVA) Price Target to $90.00

Corteva (NYSE:CTVA) had its price target raised by analysts at Deutsche Bank Aktiengesellschaft from $85.00 to $90.00 in a research report issued on Thursday,MarketScreener reports. The brokerage currently has a “buy” rating on the stock. Deutsche Bank Aktiengesellschaft’s target price suggests a potential upside of 23.92% from the company’s previous close.

A number of other analysts have also issued reports on CTVA. Weiss Ratings reissued a “hold (c-)” rating on shares of Corteva in a research report on Monday, December 29th. Bank of America increased their target price on shares of Corteva from $80.00 to $82.00 and gave the stock a “buy” rating in a research report on Thursday, January 8th. Royal Bank Of Canada lifted their target price on shares of Corteva from $80.00 to $89.00 and gave the company an “outperform” rating in a research note on Thursday. Wells Fargo & Company upped their price target on shares of Corteva from $77.00 to $85.00 and gave the stock an “overweight” rating in a research note on Thursday. Finally, Wall Street Zen upgraded Corteva from a “hold” rating to a “buy” rating in a report on Saturday, January 17th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, Corteva has a consensus rating of “Moderate Buy” and an average price target of $82.37.

Corteva Stock Performance

Shares of Corteva stock opened at $72.63 on Thursday. Corteva has a 12 month low of $53.40 and a 12 month high of $77.41. The company has a quick ratio of 1.07, a current ratio of 1.43 and a debt-to-equity ratio of 0.07. The stock has a market cap of $49.08 billion, a PE ratio of 45.97, a price-to-earnings-growth ratio of 1.84 and a beta of 0.75. The business has a fifty day simple moving average of $68.82 and a 200-day simple moving average of $68.42.

Corteva (NYSE:CTVA) last announced its quarterly earnings data on Tuesday, February 3rd. The company reported $0.22 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.22. Corteva had a return on equity of 9.06% and a net margin of 6.29%.The firm had revenue of $3.91 billion during the quarter, compared to the consensus estimate of $4.23 billion. During the same period in the prior year, the business earned $0.32 EPS. The business’s revenue for the quarter was down 1.7% on a year-over-year basis. Corteva has set its FY 2026 guidance at 3.450-3.700 EPS. On average, sell-side analysts anticipate that Corteva will post 2.96 EPS for the current fiscal year.

Hedge Funds Weigh In On Corteva

Institutional investors have recently bought and sold shares of the stock. Gladwyn Financial Advisors Inc. acquired a new position in shares of Corteva during the 2nd quarter valued at about $25,000. Total Investment Management Inc. bought a new stake in Corteva during the second quarter worth approximately $27,000. Activest Wealth Management grew its holdings in Corteva by 118.3% during the third quarter. Activest Wealth Management now owns 369 shares of the company’s stock valued at $25,000 after purchasing an additional 200 shares during the last quarter. Curat Global LLC raised its position in shares of Corteva by 93.7% in the second quarter. Curat Global LLC now owns 370 shares of the company’s stock valued at $28,000 after purchasing an additional 179 shares during the period. Finally, JPL Wealth Management LLC acquired a new stake in shares of Corteva in the third quarter worth $25,000. 81.54% of the stock is currently owned by institutional investors.

Trending Headlines about Corteva

Here are the key news stories impacting Corteva this week:

• Positive Sentiment: Several sell‑side firms lifted targets and kept bullish ratings, signaling analyst confidence in longer‑term upside: Deutsche Bank to $90 (buy), Wolfe Research to $86 (outperform), and RBC to $89 (outperform). Deutsche Bank raise Wolfe Research raise RBC raise
• Positive Sentiment: Brokerage consensus remains constructive (consensus “Moderate Buy”), which supports demand for the shares despite near‑term noise. Consensus Moderate Buy
• Positive Sentiment: Strategic commentary highlights Corteva’s expanding role in global agriculture and technology leadership—positive for medium‑term growth expectations. Corteva expands role
• Neutral Sentiment: Analyst views are mixed across publications — some highlight long‑term upside tied to licensing and settlements, while others argue valuation limits near‑term gains. Investors should weigh catalyst timing. Bull case analysis Conflicting analyst views
• Neutral Sentiment: Technical analysis pieces warn of a key structural test — useful for traders but not definitive for fundamentals; could increase short‑term volatility. Technical caution
• Negative Sentiment: Q4 results missed revenue expectations (seasonal timing and weaker crop‑protection/seed demand); revenue miss and a wider loss drove an after‑hours selloff. Those operational misses are the main near‑term headwind. Q4 revenue miss After‑hours fall
• Negative Sentiment: JPMorgan downgraded Corteva from overweight to neutral (citing valuation/limited near‑term upside), which can cool momentum among institutional buyers. JPMorgan downgrade
• Negative Sentiment: Market reaction to the earnings miss (seasonal timing) and mixed guidance elements increases short‑term uncertainty even as analysts argue for longer‑term upside — expect higher intraday volatility. Seasonal timing impact

Corteva Company Profile

Corteva, Inc (NYSE: CTVA) is an independent global agriculture company that was established as a publicly traded firm in mid‑2019 following the separation of the agriculture businesses from DowDuPont. The company focuses on delivering technologies and products that help farmers increase productivity and manage crop health. Corteva’s operations combine seed genetics, crop protection chemistries, digital tools and biological solutions to address the full cycle of crop production.

Core business activities include research and development of seed genetics and trait technologies, formulation and sale of crop protection products (such as herbicides, insecticides and fungicides), and the development of seed treatments and biologicals.